JonesTrading analyst Soumit Roy has maintained their neutral stance on CLLS stock, giving a Hold rating today.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Soumit Roy has given his Hold rating due to a combination of factors surrounding Cellectis SA’s current and future prospects. The company’s focus on the pivotal Phase 2 trial for lasme-cel in 3L+ B-ALL, expected to start in the fourth quarter of 2025, is a significant factor. The anticipated interim analysis from this trial in late 2026 and the potential BLA submission in 2028 are key milestones that contribute to the Hold rating.
Additionally, Cellectis’s financial position, with approximately $225 million in cash and equivalents as of September 2025, provides a stable foundation but also highlights the importance of careful cash management given the estimated annual cash burn. The upcoming data presentations, such as the correlation between alemtuzumab exposure and response depth at ASH 2025, and the full Phase 1 data for Eti-cel in 2026, are crucial for future evaluations. These elements suggest a cautious approach, justifying the Hold rating as the company progresses through these pivotal stages.
In another report released today, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $3.50 price target.